Seven million deaths annually are attributed to air pollution-related illnesses like COPD, lung cancer and respiratory infections. The Forum of International Respiratory Societies (FIRS), calls on ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. Currently available treatments for IPF are limited with ...

Clifton A. Klabunde passed into the arms of the Lord and his Savior on September 11, 2024 in the hospital with his family and friends at his side at age 77 of pulmonary fibrosis (lung disease). Cliff ...

In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.